Identification of novel glycosylation events on human serum-derived factor IX.

Beam-type collision-induced dissociation Coagulation factors Electron-transfer dissociation Glycoproteomics N-linked glycosylation O-linked glycosylation

Journal

Glycoconjugate journal
ISSN: 1573-4986
Titre abrégé: Glycoconj J
Pays: United States
ID NLM: 8603310

Informations de publication

Date de publication:
08 2020
Historique:
received: 28 11 2019
accepted: 24 03 2020
revised: 06 03 2020
pubmed: 8 5 2020
medline: 10 6 2021
entrez: 8 5 2020
Statut: ppublish

Résumé

Human Factor IX is a highly post-translationally modified protein that is an important clotting factor in the blood coagulation cascade. Functional deficiencies in Factor IX result in the bleeding disorder haemophilia B, which is treated with plasma-derived or recombinant Factor IX concentrates. Here, we investigated the post-translational modifications of human serum-derived Factor IX and report previously undescribed O-linked monosaccharide compositions at serine 141 and a novel site of glycosylation. At serine 141 we observed two monosaccharide compositions, with HexNAc

Identifiants

pubmed: 32378017
doi: 10.1007/s10719-020-09922-2
pii: 10.1007/s10719-020-09922-2
doi:

Substances chimiques

Monosaccharides 0
Serine 452VLY9402
Factor IX 9001-28-9

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

471-483

Auteurs

Cassandra L Pegg (CL)

School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD, 4072, Australia.

Lucia F Zacchi (LF)

Centre for Biopharmaceutical Innovation, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, QLD, 4072, Australia.

Dinora Roche Recinos (DR)

Centre for Biopharmaceutical Innovation, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, QLD, 4072, Australia.

Christopher B Howard (CB)

Centre for Biopharmaceutical Innovation, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, QLD, 4072, Australia.

Benjamin L Schulz (BL)

School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD, 4072, Australia. b.schulz@uq.edu.au.
Centre for Biopharmaceutical Innovation, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, QLD, 4072, Australia. b.schulz@uq.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH